|
|||||
|
|
| Tumor-specific lytic path “hyperploid progression mediated death”: Resolving side effects through targeting retinoblastoma or p53 mutant | |
| 摘 要： | |
| 收稿时间： | 2020-09-11 |
| 点击此处可从《World journal of clinical oncology》浏览原始摘要信息 | |
|
||||||||||||
|
||||||||||||
|
||||||||||||
|
|
|
|
| 设为首页 | 免责声明 | 关于勤云 | 加入收藏 |
|
Copyright©北京勤云科技发展有限公司 京ICP备09084417号 |